Citigroup
NKTR icon

Citigroup’s Nektar Therapeutics NKTR Stock Holding History

Citigroup’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-5,387
Closed -$1.37M – 7022
2020
Q4 		$1.37M Buy
5,387
+87
+2% +$22.5K ﹤0.01% 3230
2020
Q3 		$1.32M Sell
5,300
-7,067
-57% -$2.22M ﹤0.01% 3028
2020
Q2 		$4.3M Sell
12,367
-1,080
-8% -$337K ﹤0.01% 2003
2020
Q1 		$3.6M Buy
13,447
+1,454
+12% +$450K ﹤0.01% 1947
2019
Q4 		$3.88M Buy
11,993
+5,853
+95% +$1.7M ﹤0.01% 2263
2019
Q3 		$1.68M Sell
6,140
-1,467
-19% -$538K ﹤0.01% 3051
2019
Q2 		$4.06M Buy
7,607
+2,134
+39% +$1.07M ﹤0.01% 2153
2019
Q1 		$2.76M Buy
5,473
+1,813
+50% +$1.07M ﹤0.01% 2327
2018
Q4 		$1.8M Buy
3,660
+2,133
+140% +$1.29M ﹤0.01% 2770
2018
Q3 		$1.4M Sell
1,527
-2,386
-61% -$2.04M ﹤0.01% 3116
2018
Q2 		$2.87M Buy
3,913
+3,640
+1,333% +$4.2M ﹤0.01% 2365
2018
Q1 		$436K Buy
273
+140
+105% +$180K ﹤0.01% 4133
2017
Q4 		$119K Sell
133
-94
-41% -$55.6K ﹤0.01% 5488
2017
Q3 		$82K Sell
227
-553
-71% -$173K ﹤0.01% 5710
2017
Q2 		$229K Sell
780
-167
-18% -$48.3K ﹤0.01% 4676
2017
Q1 		$333K Sell
947
-326
-26% -$73.3K ﹤0.01% 4211
2016
Q4 		$234K Buy
1,273
+966
+315% +$196K ﹤0.01% 5150
2016
Q3 		$79K Buy
307
+234
+321% +$60.3K ﹤0.01% 5359
2016
Q2 		$16K Sell
73
-107
-59% -$23.9K ﹤0.01% 6284
2016
Q1 		$37K Sell
180
-233
-56% -$44.8K ﹤0.01% 6262
2015
Q4 		$104K Buy
413
+13
+3% +$2.67K ﹤0.01% 5342
2015
Q3 		$66K Sell
400
-140
-26% -$24.8K ﹤0.01% 5248
2015
Q2 		$101K Buy
+540
New +$92.9K ﹤0.01% 4984

Other funds holding NKTR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Citigroup's NKTR Position: Q1 2026 in Review

Citigroup reduced its Nektar Therapeutics (NKTR) stake by 30% in Q1 2026, selling an estimated $611K and leaving 25,048 shares worth $1.8M. The position accounts for ﹤0.01% of the portfolio, ranked #2728.

Citigroup first reported a position in NKTR in Q2 2013 and has held it in 52 quarters since. The position peaked at $5.47M in Q3 2018. 215 funds tracked by Wall St. Rank hold NKTR as of Q1 2026.

  • Citigroup held 25,048 shares of Nektar Therapeutics worth $1.8M as of Q1 2026.
  • Citigroup sold 10,729 Nektar Therapeutics shares in Q1 2026, an estimated $611K.
  • Nektar Therapeutics made up ﹤0.01% of Citigroup's portfolio in Q1 2026, its #2728 holding.
  • Citigroup first reported a position in Nektar Therapeutics in Q2 2013 and has held it in 52 quarters since.
  • Citigroup's Nektar Therapeutics position peaked at $5.47M in Q3 2018.
  • 215 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q1 2026.

Based on Citigroup's 13F filing for Q1 2026, filed 11 May 2026.